Clinical Trials in China / NCT07330362
Recruiting
Observational
The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.
NCT07330362 · tracked via the Priya Life Science China tracker
Condition(s) studied
Chronic GlomerulonephritisChronic Kidney Disease
Study summary
This research project aims to collect images from patients with chronic glomerulonephritis. For each subject, the images obtained from renal biopsy will undergo evaluation by both the diagnostic model and the 'gold standard' diagnosis by pathologists. The researchers will test the subjects using the diagnostic model and compare the results with the known 'gold standard' diagnosis, in order to evaluate the AUC, specificity, and sensitivity of the diagnostic model.
Eligibility
Inclusion Criteria:
1. Voluntary signing of informed consent form;
2. Patients clinically diagnosed or suspected of having chronic kidney disease according to the 2023 KDIGO Clinical Practice Guideline for the Evaluation and Management of Kidney Disease;
3. Undergoing renal biopsy and pathological specimen preparation.
Exclusion Criteria:
1. Biopsy tissue from donor kidney or transplanted kidney;
2. Poor quality of pathological specimen, unable to conduct pathological diagnosis.
Primary outcome measure(s)
- The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the TEM-AID artificial intelligence model — baseline
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the TEM-AID artificial intelligence model for candidates will be calculated.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Nanfang Hospital | Guangzhou | Guangdong | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou | Guangdong | Recruiting |
More Zhujiang Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07330362 on ClinicalTrials.gov ↗ ← All trials in China